Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the Netherlands, the United States, and China, has struck a partnership with Dr. Michael S. Diamond from Washington University School of Medicine in St. Louis. This collaboration aims to explore viral disease fields that are currently underrepresented in monoclonal antibody (mAb) therapy, such as western equine encephalitis virus (WEEV), rabies, and severe fever with thrombocytopenia syndrome virus (SFSTV).
Leveraging Nona Bio’s H2L2 Transgenic Mouse Platform Technology
Nona Bio will utilize its globally patented all-human antibody H2L2 transgenic mouse platform technology, along with its advanced technology and experience in antibody discovery and therapeutic innovation. This collaboration with Dr. Michael S. Diamond’s team is expected to drive breakthroughs in the field of antiviral therapy, ultimately improving patient life.
Dr. Michael S. Diamond’s Expertise and Contributions
Dr. Michael S. Diamond is a professor of medicine, molecular microbiology, and pathological immunology at the University of Washington School of Medicine in St. Louis. His laboratory focuses on studying the molecular basis of RNA viruses and the mechanisms of interaction between pathogens and host immunity. This research has identified multiple key components of the innate and adaptive immune systems, providing valuable insights for the development of effective antiviral treatments.-Fineline Info & Tech
